All the news

Bluepharma Group finishes 2020 with a growth of over 20% and the turnover reached 75M €

09.02.2021 in Bluepharma

Bluepharma celebrates 20 years and prepares a investment of 200 million euros


Bluepharma Group celebrates 20 years in 2021, the year in which it prepares a strategic growth plan that represents an investment of 200 million euros for the next 10 years. In 2020, Bluepharma Group's unconsolidated turnover reached 75 million euros, the result of a growth that exceeded 20%.

“2020 was a very positive year for Bluepharma. It was a year of consolidation, a lot of work and, once again, a strong bet in innovation and exports. Key factors for us that also contributed to closing the year with this growth of over 20%”, says Paulo Barradas Rebelo, president of Bluepharma. “We currently supply more than 100 companies and export, around 88% of production, to more than 40 countries, something that places us among the 1000 largest companies operating in Portugal and among the largest exporters at national level”, he adds.

In 2021, the year in which it celebrates its 20th anniversary, the pharmaceutical group presents in its strategic growth plan, the project “Bluepharma Acelera 2030”, which will be concluded in 2022, with the expansion of the current facilities, in São Martinho (Coimbra), as well as the construction of a new industrial unit "state of the art" for the production of potent solid oral forms, in Eiras (Coimbra), a global investment close to 50M €.

Also within the scope of this investment plan, the construction of the Bluepharma Park is planned, which will give rise to the largest technological park in the pharmaceutical cluster, nationwide, in a total area of 6.5 hectares, with 35 thousand square meters of covered area, and whose investment will be more than 150M €.

The President of Bluepharma reveals that "in 2021 Bluepharma will enter the phase of Accelerated Growth to which all these highly technological, sophisticated and innovative projects, which promote high added value exports" contribute a lot ".

“In these almost 20 years, we have developed technologies mainly for the international market and we have established several partnerships worldwide, therefore, we believe that the future will be one of growth, as it has been until now”, concludes the President of Bluepharma.